As scIgG-T has less capability of FcγRs engagement in comparison with trastuzumab, the reduced HER2 downregulation by scIgG-T supports the notion that HER2 downregulation in cancer cells requires active engagement of immune cells by the antibody Fc. Here, ERBB2 is linked to cancer.